Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.

ABSTRACT:

SUBMITTER: Pajon R

PROVIDER: S-EPMC8809504 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.

Pajon Rolando R Doria-Rose Nicole A NA Shen Xiaoying X Schmidt Stephen D SD O'Dell Sijy S McDanal Charlene C Feng Wenhong W Tong Jin J Eaton Amanda A Maglinao Maha M Tang Haili H Manning Kelly E KE Edara Venkata-Viswanadh VV Lai Lilin L Ellis Madison M Moore Kathryn M KM Floyd Katharine K Foster Stephanie L SL Posavad Christine M CM Atmar Robert L RL Lyke Kirsten E KE Zhou Tongqing T Wang Lingshu L Zhang Yi Y Gaudinski Martin R MR Black Walker P WP Gordon Ingelise I Guech Mercy M Ledgerwood Julie E JE Misasi John N JN Widge Alicia A Sullivan Nancy J NJ Roberts Paul C PC Beigel John H JH Korber Bette B Baden Lindsey R LR El Sahly Hana H Chalkias Spyros S Zhou Honghong H Feng Jing J Girard Bethany B Das Rituparna R Aunins Anne A Edwards Darin K DK Suthar Mehul S MS Mascola John R JR Montefiori David C DC

The New England journal of medicine 20220126 11

PMID: 35081298

Similar Datasets

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization.

Project description:The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested for neutralizing activity against Omicron and compared to neutralization titers against D614G and Beta in live virus and pseudovirus assays. Omicron was 41-84-fold less sensitive to neutralization than D614G and 5.3-7.4-fold less sensitive than Beta when assayed with serum samples obtained 4 weeks after 2 standard inoculations with 100 μg mRNA-1273. A 50 μg boost increased Omicron neutralization titers and may substantially reduce the risk of symptomatic vaccine breakthrough infections.

| S-EPMC8687471 | biostudies-literature

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.

Project description: Not available

| S-EPMC9511611 | biostudies-literature

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination.

Project description: Not available

| S-EPMC9483497 | biostudies-literature

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant.

Project description: Not available

| S-EPMC9295091 | biostudies-literature

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant.

Project description:The SARS-CoV-2 Omicron variant evades vaccine-induced immunity. While a booster dose of ancestral mRNA vaccines effectively elicits neutralizing antibodies against variants, its efficacy against Omicron in older adults, who are at the greatest risk of severe disease, is not fully elucidated. Here, we evaluate multiple longitudinal immunization regimens of mRNA BNT162b2 to assess the effects of a booster dose provided >8 months after the primary immunization series across the murine lifespan, including in aged 21-month-old mice. Boosting dramatically enhances humoral and cell-mediated responses with evidence of Omicron cross-recognition. Furthermore, while younger mice are protected without a booster dose, boosting provides sterilizing immunity against Omicron-induced lung infection in aged 21-month-old mice. Correlational analyses reveal that neutralizing activity against Omicron is strongly associated with protection. Overall, our findings indicate age-dependent vaccine efficacy and demonstrate the potential benefit of mRNA booster immunization to protect vulnerable older populations against SARS-CoV-2 variants.

| S-EPMC9357006 | biostudies-literature

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination.

Project description: Not available

| S-EPMC8761745 | biostudies-literature

Maternal and Neonatal SARS-CoV-2 Omicron Variant Neutralization after Antenatal mRNA Vaccination.

Project description:We evaluated the neutralization efficiency against SARS-CoV-2 omicron variant in maternal and cord blood sera after antenatal BNT162b2 vaccination. Neutralizing antibodies against omicron were lacking at the time of delivery after two-dose vaccination. A third booster dose was essential in building neutralizing antibody capacity against omicron among mothers and neonates.

| S-EPMC9213860 | biostudies-literature

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children.

Project description:BackgroundThe highly transmissible severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant is a global concern. This study assessed the neutralization activity of two-dose regimens of mRNA-1273 vaccination against Omicron in adults, adolescents and children.MethodsNeutralizing activity against the Omicron variant was evaluated in serum samples from adults (≥18 years) in the phase 3, Coronavirus Efficacy (COVE) and from adolescents (12-17 years) in the TeenCOVE trials following a two-dose regimen of 100 μg mRNA-1273 and from children (6-<12 years) in the KidCOVE trial administered two doses of 50 μg mRNA-1273. Neutralizing antibody geometric mean ID50 titers (GMT) were measured using a lentivirus-based pseudovirus neutralizing assay at day 1 and 4 weeks (day 57) following the second mRNA-1273 dose, compared with wild-type (D614G).ResultsAt 4 weeks following a second dose of mRNA-1273 (100 μg), the GMT was reduced 28.8-fold compared with D614G in adults (≥18 years). In adolescents (12-17 years), the GMT was 11.8-fold lower than D614G, 4 weeks after a second dose of mRNA-1273 (100 μg), and compared with adults, were 1.5- and 3.8-fold higher for D614G and the Omicron variant, respectively. In children (6-<12 years), 4 weeks post-second dose of 50 μg mRNA-1273, Omicron GMTs were reduced 22.1-fold versus D614G and were 2.0-fold higher for D614G and 2.5-fold higher for Omicron compared with adults.ConclusionsA two-dose regimen of 100 μg mRNA-1273 in adolescents and of 50 μg in children elicited neutralization responses against the Omicron variant that were reduced compared with the wild-type D614G, and numerically higher than those in adults.

| S-EPMC8811908 | biostudies-literature

Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant.

Project description:The emergence of the new SARS-CoV-2 Omicron variant, which is known to accumulate a huge number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. In this scenario, we evaluated the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. The percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 17% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times, indicating a positive impact of this vaccine combination in the serological immune response.

| S-EPMC8963699 | biostudies-literature

Neutralization of SARS-CoV-2 omicron after BBIBP-CorV and ZF2001 booster vaccination.

Project description: Not available

| S-EPMC9762096 | biostudies-literature